Delhi High Court Bars Pharma Firm From Copying Finecure's Website, Product Packaging

Justice Tejas Karia passed the ad-interim injunction in a copyright infringement suit filed by Finecure against Nilesh Jain and M/s Cubit Lifesciences LLP.

Finecure told the Court that it had been engaged in the pharmaceutical and nutraceutical business since 1996 and owned copyright registration covering original artistic and literary works on its website.

These included text, product descriptions, articles, photographs, images, graphics, layout, colour scheme and overall design.

The company alleged that the defendants' website, www.cubitlifesciences.com, substantially reproduced its copyrighted material without authorisation. Finecure said it discovered the website in the fourth week of October 2026 and had a screen recording made on October 27.

According to Finecure, the defendants had reproduced its corporate identity and particulars, adopted its tagline “Making Lives Healthier” as their own mission, and displayed photographs of its product packs, including FINEMOX, FINETRIAX, BPGARD, CAROSU, MYNERVE, RABIFINE, PEPCARE and MENUVIT.

The company further alleged that the defendants had reproduced substantial portions of its website's text, layout and design, and represented its business credentials, manufacturing capacities, workforce, awards and product portfolio as their own to solicit business.

Finecure also submitted that the defendants were familiar with its business since 2014, when Defendant No. 3 had entered into an agreement with it for third-party manufacturing of pharmaceutical preparations.

The Court observed that the material on record, including the copyright registration and assignment letter, lent prima facie support to Finecure's claim. A comparison of the two websites revealed substantial reproduction of its original content, photographs, graphics and product packaging artwork.

Finding a prima facie case of copyright infringement, the Court held that the balance of convenience lay in Finecure's favour and that continued unauthorised use could harm its reputation and commercial interests.

Accordingly, it restrained the defendants, their partners, officers and agents from uploading, reproducing, publishing or communicating Finecure's copyrighted works to the public in any manner amounting to infringement.

The matter is next listed on March 3, 2027.

For Finecure: Senior Advocate Swathi Sukumar with Advocates Nirupam Lodha, Asim Chaturvedi, Shashwat Rakshit & Nidhi Pathak